Novo Heal is developing first-in-class therapies that guide the body's own healing to restore tissue function.
Get in TouchNovo Heal is a preclinical company focused on developing regenerative therapies. Our primary program targets vocal fold fibrosis — a condition that permanently impairs voice function with no existing restorative treatment.
Our approach is rooted in over a decade of NIH R01 awards, scrutinized by peer-reviewed publications, and validated by an NSF STTR Phase I award. Novo Heal is positioned to bring a genuinely transformative therapy to patients and clinicians.
Unlike current treatments that offer only temporary symptom relief, our product actively modulates the wound environment to promote regenerative healing.
Demonstrated reduction in key myofibroblast markers and restoration of tissue pliability to healthy levels in vivo.
Inhibition of inflammatory macrophage activation while promoting pro-healing phenotypes, guiding the wound microenvironment toward resolution.
Patented processes enable consistent, reproducible production — designed to fit seamlessly into existing clinical workflows.
Whether you're an investor, clinician, or potential collaborator, we'd welcome the conversation. Reach out and our team will follow up.